Instead of using all the transcripts as reference for the RNA-seq analysis, can I use a small subset which I am interested? I compared the results, of course, the expression values from the small subset is higher than that from the whole set. What I'm concerned is that, Does it cause any bias to the expression values?
-
-
This will depend upon how you do your mapping and then the expression quantitation. -
I used RNA-seq analysis in CLC genomic workbench.Originally posted by dpryan View Post
Set parameters is as below
Minimum length fraction: 0.9
Minimum similarity fraction: 0.8
Maximum number of hits for a read: 10
What is the right way to do the mapping and quantitation for a small subset reference? I really appreciate if you can provide a reference for this. Thank you very much!Comment
-
I don't think it's a good idea. It's always better to map to all the transcript because your data is coming from total RNA ( or poly-A RNA). It can happen that when you map to your subset, some reads maybe map in a better way to transcript that are not in your subset..Comment
-
Yes, you're right. It is more robust to use entire assembly, since the result would be normalized by the entire mRNA expression, and also much easier for downstream analysis.Originally posted by NicoBxl View PostComment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment